<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HCE592AA8A0214973AE0F98BD9E74C969" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 5708 IH: MCM PRV Reauthorization Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-09-26</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5708</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230926">September 26, 2023</action-date><action-desc><sponsor name-id="F000475">Mr. Finstad</sponsor> (for himself and <cosponsor name-id="P000616">Mr. Phillips</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to extend a priority review program to encourage treatments for agents that present national security threats.</official-title></form><legis-body id="H3F9B7101604F46E3B7836AD7E2D27B44" style="OLC"><section id="HBB232E2ABACA4483BC5D26F35CDF6C61" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>MCM PRV Reauthorization Act</short-title></quote>. </text></section><section id="H0B759E72CE774CCA8FC13F6DD51C73A0"><enum>2.</enum><header>Extension of priority review to encourage treatments for agents that present national security threats</header><text display-inline="no-display-inline">Section 565A(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbbâ€“4a(g)) is amended by striking <quote>2023</quote> and inserting <quote>2033</quote>. </text></section></legis-body></bill> 

